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by some margin, the commonest clinical presentation of
lower limb peripheral arterial disease (PAD). It is likely,
therefore, that even before Charcot described the
syndrome and coined the term intermittent claudication
(IC) in 1858 (from the Latin, claudicatio, meaning to limp,
apparently after the Emperor Claudius), millions of
affected individuals across the world will have sought
medical advice and undergone treatment for this condition.
As such, it would probably be reasonable for patients to
assume that those purporting to be experts in, and offering
therapeutic intervention for, IC would have had ample
opportunity to conduct high-quality research into this
condition and so have at their disposal a large body of
reliable and credible evidence on which to base their
treatment recommendations. However, nothing could be
further from the truth, as the evidence base underpinning
the treatment of IC remains embarrassingly poor. Almost 25
years after Perkins and his colleagues started randomising
patients, there is still no consensus regarding the relative
merits of (supervised) exercise and interventional treat-
ment (angioplasty, stenting, surgery) for this large and
heterogeneous patient population. What Perkins et al. did
show, in their seminal randomised controlled trial (RCT),
was that patients with IC are at high risk for cardiovascular
death, but at low risk of amputation and that exercise
therapy was superior to angioplasty in terms of walking
distance at least in the medium term. In the longer term,
both exercise and intervention were equally effective, or
perhaps equally ineffective, depending on whether your
glass in life is half full or half empty.
A British Medical Association Medline search of ‘inter-
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published on the subject. However, with great respect to
the authors, it is only a tiny minority of these “post-Per-
kins” papers that provide any credible evidence on which to
base clinical practice. Disappointingly, even the subsequent
RCTs, when subjected to rigorous scrutiny (www.
gradeworkinggroup.org) by bodies such as the UK’s
National Institute for Health and Clinical Excellence (NICE)
(www.nice.org.uk) for the purposes of Clinical Guideline
Development, are usually found to be seriously methodo-
logically flawed and to provide low quality evidence in
which the organisation (and healthcare commissioners and
purchasers) can have little confidence.
However, there are a dozen or so RCTs that have
compared various forms of supervised and unsupervised
exercise and these fairly consistently show that supervision
leads to more clinically meaningful, and significantly
greater improvements in walking distance; although what
form and duration of supervised exercise is most effective
remains unclear. There are less than ten reasonable RCTs
(including the Oxford trial), that when combined have
randomised just a few hundred patients to different types
of exercise therapy and various surgical and endovascular
interventions. This tiny and heterogeneous data set has
been subjected to endless interpretation, re-interpre
tation and over-interpretation, resulting in a wide range
of views as to what they show, or don’t show. Accordingly, I
would respectfully suggest that the average patient would
have to conclude that there is little evidence to support the
high costs, and small but real risks associated with inter-
vention, over and above best medical therapy (BMT) and
exercise therapy, for the vast majority of patients.
Why is it that even in the UK (which must have one of the
most tightly regulated and “evidence based” healthcare
systems in the world), that as a vascular and endovascular
surgeon, I appear to be at liberty to insert expensive (even
drug eluting) stents in the superficial femoral artery ford by Elsevier Ltd. All rights reserved.
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access to a supervised exercise programme. Moreover,
many of the patients who are sent to me (presumably for
intervention?) with a primary care diagnosis of IC are still
smoking, have uncontrolled blood pressure, have untreated
hypercholesterolemia, are not on anti-platelet agents, and
not infrequently have undiagnosed diabetes. Once again,
our hypothetical, reasonably educated, but non-specialist
patient might be surprised, shocked and perhaps even
angry that his hard-earned taxes are apparently being spent
so unwisely on admittedly sexy, but very expensive and
evidence-free, “gizmology”. The logic and drivers under-
pinning the treatment of IC has been even harder for me to
fathom in many of the hospitals and clinics I have had the
privilege to visit in other parts of the world; however,
suffice to say that economics often appear to be an
important factor in clinical decision making.
Looking back at the Perkins paper it is easy to be critical;
small numbers, incomplete follow-up, mixing femoro-
popliteal and aorto-iliac disease, less than optimal
medical therapy and so on. However, at the time, it seta new standard for scientific reporting in our specialty and
even today, it is quite rightly cited far and wide in the IC
literature as one of the seminal papers in the field.
What is so disappointing is that, almost 25 years later,
we still do not appear to have moved on very much, if at all.
Yes, the “gizmology” has improved beyond all recognition
but, in truth, we still do not know how and when that
technology should be used and, crucially, how much we
should be expected to pay for it, given the, often very
modest, clinical ‘value-added’ claimed. IC is a common and
disabling condition that affects more than 1 in 20 of our
increasingly ageing population. Surely we can, and we
must, raise our game and do the necessary research so that
we provide a clinical and cost-effective package of care for
these people; care that is driven by health need and sound
evidence and not by (endo)-vascular ego or personal and
corporate profit.
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